Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24343466 | 0.96 | DHFR (0.43) | DHFRSLC19A1 | |
| SCHEMBL25725529 | 0.93 | DHFR (0.34) | DHFR | |
| SCHEMBL24344198 | 0.92 | DHFR (0.43) | DHFRSLC19A1 | |
| SCHEMBL25729795 | 0.91 | DHFR (0.44) | DHFR | |
| SCHEMBL30311353 | 0.91 | DHFR (0.44) | DHFR | |
| SCHEMBL24192567 | 0.91 | DHFR (0.44) | DHFR | |
| SCHEMBL24344143 | 0.90 | DHFR (0.42) | DHFR | |
| SCHEMBL24343460 | 0.89 | DHFR (0.41) | DHFR | |
| SCHEMBL25731882 | 0.89 | DHFR (0.39) | DHFR | |
| SCHEMBL25833184 | 0.89 | DHFR (0.42) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | DHFR 1/4885KDM4E 2050/4885MEN1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.